Increased	O
Enoxaparin	B:C0206460
Dosing	O
for	O
Venous	O
Thromboembolism	I:C0199242
Prophylaxis	I:C0199242
in	O
General	O
Trauma	O
Patients	O
.	O

Increased	O
Enoxaparin	O
Dosing	O
for	O
Venous	B:C0199242
Thromboembolism	I:C0199242
Prophylaxis	I:C0199242
in	O
General	O
Trauma	O
Patients	O
.	O

Increased	O
Enoxaparin	O
Dosing	O
for	O
Venous	O
Thromboembolism	I:C0199242
Prophylaxis	I:C0199242
in	O
General	O
Trauma	B:C3714660
Patients	O
.	O

To	O
review	O
the	O
evidence	O
regarding	O
increased	O
enoxaparin	B:C0206460
dosing	O
for	O
venous	O
thromboembolism	I:C0199242
(	I:C0199242
VTE	I:C0199242
)	I:C0199242
prophylaxis	I:C0199242
in	O
the	O
general	O
trauma	O
patient	O
population	O
.	O

To	O
review	O
the	O
evidence	O
regarding	O
increased	O
enoxaparin	O
dosing	O
for	O
venous	B:C0199242
thromboembolism	I:C0199242
(	I:C0199242
VTE	I:C0199242
)	I:C0199242
prophylaxis	I:C0199242
in	O
the	O
general	O
trauma	O
patient	O
population	O
.	O

To	O
review	O
the	O
evidence	O
regarding	O
increased	O
enoxaparin	O
dosing	O
for	O
venous	O
thromboembolism	I:C0199242
(	I:C0199242
VTE	I:C0199242
)	I:C0199242
prophylaxis	I:C0199242
in	O
the	O
general	O
trauma	B:C3714660
patient	O
population	O
.	O

To	O
review	O
the	O
evidence	O
regarding	O
increased	O
enoxaparin	O
dosing	O
for	O
venous	O
thromboembolism	I:C0199242
(	I:C0199242
VTE	I:C0199242
)	I:C0199242
prophylaxis	I:C0199242
in	O
the	O
general	O
trauma	O
patient	O
population	B:C1257890
.	O

A	O
search	O
of	O
MEDLINE	B:C0025141
databases	I:C0025141
(	O
1946	O
to	O
October	O
2016	O
)	O
was	O
conducted	O
using	O
the	O
search	O
terms	O
enoxaparin	O
,	O
thromboembolism	O
prophylaxis	I:C0199242
,	O
venous	O
thromboembolism	I:C1861172
,	O
trauma	O
,	O
anti-factor	O
Xa	I:C0443793
,	O
and	O
weight	O
-	O
based	O
dosing	O
.	O

A	O
search	O
of	O
MEDLINE	O
databases	I:C0025141
(	O
1946	O
to	O
October	O
2016	O
)	O
was	O
conducted	O
using	O
the	O
search	O
terms	O
enoxaparin	B:C0206460
,	O
thromboembolism	O
prophylaxis	I:C0199242
,	O
venous	O
thromboembolism	I:C1861172
,	O
trauma	O
,	O
anti-factor	O
Xa	I:C0443793
,	O
and	O
weight	O
-	O
based	O
dosing	O
.	O

A	O
search	O
of	O
MEDLINE	O
databases	I:C0025141
(	O
1946	O
to	O
October	O
2016	O
)	O
was	O
conducted	O
using	O
the	O
search	O
terms	O
enoxaparin	O
,	O
thromboembolism	B:C0199242
prophylaxis	I:C0199242
,	O
venous	O
thromboembolism	I:C1861172
,	O
trauma	O
,	O
anti-factor	O
Xa	I:C0443793
,	O
and	O
weight	O
-	O
based	O
dosing	O
.	O

A	O
search	O
of	O
MEDLINE	O
databases	I:C0025141
(	O
1946	O
to	O
October	O
2016	O
)	O
was	O
conducted	O
using	O
the	O
search	O
terms	O
enoxaparin	O
,	O
thromboembolism	O
prophylaxis	I:C0199242
,	O
venous	B:C1861172
thromboembolism	I:C1861172
,	O
trauma	O
,	O
anti-factor	O
Xa	I:C0443793
,	O
and	O
weight	O
-	O
based	O
dosing	O
.	O

A	O
search	O
of	O
MEDLINE	O
databases	I:C0025141
(	O
1946	O
to	O
October	O
2016	O
)	O
was	O
conducted	O
using	O
the	O
search	O
terms	O
enoxaparin	O
,	O
thromboembolism	O
prophylaxis	I:C0199242
,	O
venous	O
thromboembolism	I:C1861172
,	O
trauma	B:C3714660
,	O
anti-factor	O
Xa	I:C0443793
,	O
and	O
weight	O
-	O
based	O
dosing	O
.	O

A	O
search	O
of	O
MEDLINE	O
databases	I:C0025141
(	O
1946	O
to	O
October	O
2016	O
)	O
was	O
conducted	O
using	O
the	O
search	O
terms	O
enoxaparin	O
,	O
thromboembolism	O
prophylaxis	I:C0199242
,	O
venous	O
thromboembolism	I:C1861172
,	O
trauma	O
,	O
anti-factor	B:C0443793
Xa	I:C0443793
,	O
and	O
weight	O
-	O
based	O
dosing	O
.	O

Additional	O
references	O
were	O
identified	O
from	O
a	O
review	B:C0282441
of	I:C0282441
literature	I:C0282441
citations	O
.	O

Additional	O
references	O
were	O
identified	O
from	O
a	O
review	O
of	I:C0282441
literature	I:C0282441
citations	B:C0552371
.	O

Search	O
results	O
were	O
limited	O
to	O
English	O
-	O
language	O
studies	B:C2603343
conducted	O
in	O
humans	O
.	O

Search	O
results	O
were	O
limited	O
to	O
English	O
-	O
language	O
studies	O
conducted	O
in	O
humans	B:C0086418
.	O

Trials	B:C0008976
that	O
included	O
only	O
obese	O
patients	O
or	O
nontrauma	O
patients	O
were	O
excluded	O
.	O

Trials	O
that	O
included	O
only	O
obese	B:C0028754
patients	O
or	O
nontrauma	O
patients	O
were	O
excluded	O
.	O

A	O
total	O
of	O
7	O
trials	B:C0008976
(	O
958	O
patients	O
)	O
explored	O
the	O
use	O
of	O
increased	O
dosing	O
of	O
enoxaparin	O
for	O
VTE	O
prophylaxis	I:C0199242
in	O
trauma	O
patients	O
.	O

A	O
total	O
of	O
7	O
trials	O
(	O
958	O
patients	O
)	O
explored	O
the	O
use	O
of	O
increased	O
dosing	O
of	O
enoxaparin	B:C0206460
for	O
VTE	O
prophylaxis	I:C0199242
in	O
trauma	O
patients	O
.	O

A	O
total	O
of	O
7	O
trials	O
(	O
958	O
patients	O
)	O
explored	O
the	O
use	O
of	O
increased	O
dosing	O
of	O
enoxaparin	O
for	O
VTE	B:C0199242
prophylaxis	I:C0199242
in	O
trauma	O
patients	O
.	O

A	O
total	O
of	O
7	O
trials	O
(	O
958	O
patients	O
)	O
explored	O
the	O
use	O
of	O
increased	O
dosing	O
of	O
enoxaparin	O
for	O
VTE	O
prophylaxis	I:C0199242
in	O
trauma	B:C3714660
patients	O
.	O

Patients	O
were	O
divided	O
by	O
enoxaparin	B:C0206460
dosing	O
strategies	O
:	O
standard	O
dosing	O
of	O
30	O
mg	O
twice	O
daily	O
(	O
BID	O
;	O
n	O
=	O
509	O
)	O
,	O
higher	O
initial	O
dosing	O
regimen	O
(	O
n	O
=	O
216	O
)	O
,	O
or	O
dosing	O
based	O
on	O
anti-FXa	O
level	I:C1318056
adjustments	O
(	O
n	O
=	O
233	O
)	O
.	O

Patients	O
were	O
divided	O
by	O
enoxaparin	O
dosing	O
strategies	O
:	O
standard	O
dosing	O
of	O
30	O
mg	O
twice	O
daily	O
(	O
BID	O
;	O
n	O
=	O
509	O
)	O
,	O
higher	O
initial	O
dosing	O
regimen	B:C0040808
(	O
n	O
=	O
216	O
)	O
,	O
or	O
dosing	O
based	O
on	O
anti-FXa	O
level	I:C1318056
adjustments	O
(	O
n	O
=	O
233	O
)	O
.	O

Patients	O
were	O
divided	O
by	O
enoxaparin	O
dosing	O
strategies	O
:	O
standard	O
dosing	O
of	O
30	O
mg	O
twice	O
daily	O
(	O
BID	O
;	O
n	O
=	O
509	O
)	O
,	O
higher	O
initial	O
dosing	O
regimen	O
(	O
n	O
=	O
216	O
)	O
,	O
or	O
dosing	O
based	O
on	O
anti-FXa	B:C1318056
level	I:C1318056
adjustments	O
(	O
n	O
=	O
233	O
)	O
.	O

Patients	O
were	O
divided	O
by	O
enoxaparin	O
dosing	O
strategies	O
:	O
standard	O
dosing	O
of	O
30	O
mg	O
twice	O
daily	O
(	O
BID	O
;	O
n	O
=	O
509	O
)	O
,	O
higher	O
initial	O
dosing	O
regimen	O
(	O
n	O
=	O
216	O
)	O
,	O
or	O
dosing	O
based	O
on	O
anti-FXa	O
level	I:C1318056
adjustments	B:C2945673
(	O
n	O
=	O
233	O
)	O
.	O

The	O
majority	O
of	O
the	O
42	O
total	O
venous	B:C1861172
thromboembolism	I:C1861172
events	O
(	O
64.3	O
%	O
)	O
occurred	O
in	O
the	O
standard	O
dosing	O
regimen	O
.	O

The	O
majority	O
of	O
the	O
42	O
total	O
venous	O
thromboembolism	I:C1861172
events	O
(	O
64.3	O
%	O
)	O
occurred	O
in	O
the	O
standard	O
dosing	O
regimen	B:C0040808
.	O

Within	O
each	O
group	O
,	O
venous	B:C1861172
thromboembolism	I:C1861172
was	O
reported	O
in	O
5.3	O
%	O
of	O
patients	O
in	O
the	O
standard	O
dosing	O
group	O
,	O
3.2	O
%	O
in	O
the	O
higher	O
initial	O
dosing	O
group	O
,	O
and	O
4	O
%	O
in	O
the	O
anti-FXa	O
adjustment	O
group	O
.	O

Within	O
each	O
group	O
,	O
venous	O
thromboembolism	I:C1861172
was	O
reported	O
in	O
5.3	O
%	O
of	O
patients	O
in	O
the	O
standard	O
dosing	O
group	O
,	O
3.2	O
%	O
in	O
the	O
higher	O
initial	O
dosing	O
group	O
,	O
and	O
4	O
%	O
in	O
the	O
anti-FXa	B:C0443793
adjustment	O
group	O
.	O

Within	O
each	O
group	O
,	O
venous	O
thromboembolism	I:C1861172
was	O
reported	O
in	O
5.3	O
%	O
of	O
patients	O
in	O
the	O
standard	O
dosing	O
group	O
,	O
3.2	O
%	O
in	O
the	O
higher	O
initial	O
dosing	O
group	O
,	O
and	O
4	O
%	O
in	O
the	O
anti-FXa	O
adjustment	B:C2945673
group	O
.	O

Initial	O
subtherapeutic	O
anti-FXa	B:C1318056
levels	I:C1318056
occurred	O
in	O
33	O
%	O
to	O
92	O
%	O
of	O
standard	O
dose	O
patients	O
and	O
9	O
%	O
to	O
39	O
%	O
of	O
higher	O
initial	O
dose	O
patients	O
.	O

The	O
average	O
weight	O
-	O
based	O
dose	O
required	O
to	O
achieve	O
a	O
therapeutic	B:C0580398
level	I:C0580398
ranged	O
between	O
0.43	O
and	O
0.54	O
mg/kg/	O
dose	O
BID	O
.	O

The	O
overall	O
rate	O
of	O
bleeding	B:C0019080
was	O
low	O
,	O
with	O
3	O
incidents	O
(	O
0.37	O
%	O
)	O
reported	O
.	O

Standard	O
-	O
dose	O
enoxaparin	B:C0206460
prophylaxis	O
may	O
not	O
be	O
optimal	O
for	O
the	O
general	O
trauma	O
patient	O
population	O
.	O

Standard	O
-	O
dose	O
enoxaparin	O
prophylaxis	B:C0199242
may	O
not	O
be	O
optimal	O
for	O
the	O
general	O
trauma	O
patient	O
population	O
.	O

Standard	O
-	O
dose	O
enoxaparin	O
prophylaxis	O
may	O
not	O
be	O
optimal	O
for	O
the	O
general	O
trauma	B:C3714660
patient	O
population	O
.	O

Standard	O
-	O
dose	O
enoxaparin	O
prophylaxis	O
may	O
not	O
be	O
optimal	O
for	O
the	O
general	O
trauma	O
patient	O
population	B:C1257890
.	O

Weight	O
-	O
based	O
enoxaparin	B:C0206460
dosing	O
(	O
0.5	O
mg	O
/kg/	O
dose	O
BID	O
)	O
is	O
an	O
option	O
in	O
trauma	O
patients	O
considered	O
to	O
be	O
at	O
a	O
lower	O
risk	O
of	O
bleeding	O
complications	O
.	O

Weight	O
-	O
based	O
enoxaparin	O
dosing	O
(	O
0.5	O
mg	O
/kg/	O
dose	O
BID	O
)	O
is	O
an	O
option	O
in	O
trauma	B:C3714660
patients	O
considered	O
to	O
be	O
at	O
a	O
lower	O
risk	O
of	O
bleeding	O
complications	O
.	O

Weight	O
-	O
based	O
enoxaparin	O
dosing	O
(	O
0.5	O
mg	O
/kg/	O
dose	O
BID	O
)	O
is	O
an	O
option	O
in	O
trauma	O
patients	O
considered	O
to	O
be	O
at	O
a	O
lower	O
risk	O
of	O
bleeding	B:C0019080
complications	O
.	O

Weight	O
-	O
based	O
enoxaparin	O
dosing	O
(	O
0.5	O
mg	O
/kg/	O
dose	O
BID	O
)	O
is	O
an	O
option	O
in	O
trauma	O
patients	O
considered	O
to	O
be	O
at	O
a	O
lower	O
risk	O
of	O
bleeding	O
complications	B:C0009566
.	O

